Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

62.44 +0.34 (+0.54%)

Delayed Quote Updated: 12:14 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about State Street SPDR S&P Pharmaceuticals ETF

< Previous 1 2 3 Next >

Better Pharma ETF: iShares IHE vs. State Street XPH ↗

October 10, 2026

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

Via The Motley Fool

Topics ETFs

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma ↗

October 10, 2026

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Via The Motley Fool

Topics ETFs

Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals ↗

October 04, 2026

XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.

Via The Motley Fool

Topics ETFs

Why Did AQST Stock Plunge 40% In Pre-Market Today? ↗

January 09, 2026

Via Stocktwits

IXJ vs XPH: Global Healthcare ETF or Pharma Focus? ↗

September 11, 2026

XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.

Via The Motley Fool

Topics ETFs

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH ↗

September 10, 2026

Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? ↗

September 10, 2026

FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.

Via The Motley Fool

Topics ETFs

XPH vs PJP: Which Pharma ETF Offers Better Value ↗

August 17, 2026

State Street's lower costs appeal to buy-and-hold investors, while Invesco's concentrated portfolio and lower volatility suit risk-averse income seekers.

Via The Motley Fool

Topics ETFs

Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH ↗

August 12, 2026

One fund targets pharma exclusively and surged 63% in a year, while the other diversifies across healthcare with lower volatility.

Via The Motley Fool

Topics ETFs Stocks

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗

July 16, 2026

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗

July 08, 2026

IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.

Via The Motley Fool

Topics ETFs

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗

July 08, 2026

Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.

Via The Motley Fool

Topics ETFs

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? ↗

June 04, 2026

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration—key factors shaping their long-term investor appeal.

Via The Motley Fool

Topics ETFs Stocks

Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗

June 04, 2026

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

Via The Motley Fool

Topics ETFs

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗

March 10, 2026

Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million.

Via Stocktwits

Topics Intellectual Property

Why Did CANF Stock Soar 40% In Pre-Market Today? ↗

March 04, 2026

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Via Stocktwits

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗

March 03, 2026

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

Via Stocktwits

Topics Workforce

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗

February 18, 2026

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

Via Stocktwits

Topics ETFs Government

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗

February 10, 2026

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

Via Stocktwits

Why Did CRMD Stock Crash 28% Today? ↗

January 08, 2026

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

Via Stocktwits

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Via Benzinga

Topics Government World Trade

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.

Via Benzinga

Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗

August 22, 2025

The tariffs will impact products imported from Europe, the Trump administration said late Thursday.

Via Investor's Business Daily

Topics ETFs Government Intellectual Property

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.

Via Benzinga

Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)

July 29, 2025

In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at...

Via MarketMinute

Topics ETFs Economy

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

Headline News about State Street SPDR S&P Pharmaceuticals ETF

Starting at /week.